| 4.315 0.035 (0.82%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.17 | 1-year : | 6.04 |
| Resists | First : | 4.42 | Second : | 5.17 |
| Pivot price | 3.86  |
|||
| Supports | First : | 3.81 | Second : | 3.43 |
| MAs | MA(5) : | 4.16 |
MA(20) : | 3.8 |
| MA(100) : | 3.55 |
MA(250) : | 5.73  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 77.9 |
D(3) : | 72.5 |
| RSI | RSI(14): 65.3 |
|||
| 52-week | High : | 14.68 | Low : | 2.59 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BCTX ] has closed below upper band by 13.1%. Bollinger Bands are 42.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.37 - 4.4 | 4.4 - 4.41 |
| Low: | 4.12 - 4.14 | 4.14 - 4.16 |
| Close: | 4.27 - 4.31 | 4.31 - 4.35 |
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
Mon, 14 Sep 2026
BriaCell (BCTX) Phase 3 Trial Safety Endorsement Highlights Mark - GuruFocus
Mon, 14 Sep 2026
A breast cancer trial gets a seventh recommendation to continue - Stock Titan
Tue, 08 Sep 2026
BriaCell Therapeutics (BCTX) Edges Higher as Shares Hold Above Key Support at $3.42 - Volume Breakout Ideas - careplusvn.com
Tue, 08 Sep 2026
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center - GlobeNewswire
Tue, 08 Sep 2026
Nature Medicine features a BriaCell trial among 11 shaping medicine in 2026 - Stock Titan
Wed, 05 Aug 2026
BriaCell Therapeutics (BCTX) Rises 3.86% to $3.5 as Immuno-Oncology Interest Builds - Block Trade Flow - careplusvn.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 399 (K) |
| Shares Short P.Month | 448 (K) |
| EPS | -0.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.31 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -90.9 % |
| Return on Equity (ttm) | -175.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -5.14 |
| PEG Ratio | 0 |
| Price to Book value | 1.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|